Establishment Labs (NASDAQ:ESTA) Hits New 52-Week High – Should You Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $90.50 and last traded at $90.4970, with a volume of 140799 shares. The stock had previously closed at $89.25.

Analyst Ratings Changes

A number of analysts have weighed in on ESTA shares. Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. BTIG Research increased their price target on Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Citigroup restated a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $87.14.

Establishment Labs Stock Performance

The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The stock has a market capitalization of $2.69 billion, a PE ratio of -61.22 and a beta of 1.06. The stock has a 50 day moving average of $75.84 and a two-hundred day moving average of $70.91.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter in the previous year, the company posted ($0.70) EPS. The company’s revenue was up 44.7% compared to the same quarter last year. Research analysts expect that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director directly owned 927,504 shares in the company, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 292,500 shares of company stock worth $20,591,021 over the last quarter. 9.99% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds have recently bought and sold shares of ESTA. Assenagon Asset Management S.A. increased its position in shares of Establishment Labs by 59.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 115,876 shares of the company’s stock valued at $8,445,000 after buying an additional 43,164 shares in the last quarter. Bamco Inc. NY boosted its position in shares of Establishment Labs by 30.2% in the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after buying an additional 274,287 shares in the last quarter. Simplify Asset Management Inc. grew its stake in Establishment Labs by 92.1% in the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock valued at $5,313,000 after acquiring an additional 34,946 shares during the last quarter. Portolan Capital Management LLC grew its stake in Establishment Labs by 24.7% in the 3rd quarter. Portolan Capital Management LLC now owns 155,096 shares of the company’s stock valued at $6,357,000 after acquiring an additional 30,704 shares during the last quarter. Finally, Mudita Advisors LLP increased its holdings in Establishment Labs by 14.3% during the 3rd quarter. Mudita Advisors LLP now owns 686,764 shares of the company’s stock valued at $28,150,000 after acquiring an additional 86,100 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.